Uterine Cancer
Adenocarcinoma of the Uterine Body
Female, 64 years
Patient Internal ID: 75680559
ICD-10 code
C54.8 Malignant Neoplasm of Overlapping Sites of Corpus Uteri
Diagnosis (Incl. Metastases/Stage) and Year
January 2017
Adenocarcinoma of the Uterine Body ypT1bN0M0 G3, LV1, Ki67 – 80%, ER (-/+), MSS. Disease progression in May 2018, Metastasis in the Liver and Bones. In October 2020 Metastasis in the Lungs.
Previous Treatment
Surgery, (Total Hysterectomy), Radiation Therapy, Chemotherapy (Carboplatin/ Paclitaxel), Surgery (Resection of Metastasis), Chemotherapy (Cisplatin/ Doxorubicin), Hormone Therapy (Tamoxifen).
Prognosis and Survival Expectation
The prognosis of Metastatic Uterine Cancer remains poor, with a 5-year relative overall survival being 15% and median survival of about ±16 months from diagnosis.
Treatment Provided
Autologous DCV (5 doses) and CIK (4 doses) over a period of 13 months.
Patient Survival/Condition and Year
Date of Review: 06/12/2023
The patient has survived for 71 months since the diagnosis and 55 months since the disease progression. It can be concluded that the addition of Immunotherapy, alongside Surgery, Chemotherapy, Hormone Therapy and Radiation Therapy, has extended patient survival by an estimate of around 39 months so far.
